|1.||Tenen, Daniel G: 23 articles (12/2010 - 01/2002)|
|2.||Koeffler, H Phillip: 10 articles (08/2012 - 02/2002)|
|3.||Zhang, Pu: 7 articles (12/2009 - 06/2002)|
|4.||Calabretta, Bruno: 7 articles (09/2008 - 01/2002)|
|5.||Gery, Sigal: 6 articles (08/2012 - 12/2003)|
|6.||Behre, Gerhard: 6 articles (12/2010 - 07/2002)|
|7.||Nerlov, Claus: 6 articles (11/2009 - 11/2003)|
|8.||Halmos, Balazs: 6 articles (02/2009 - 01/2002)|
|9.||Dayaram, Tajhal: 6 articles (08/2006 - 06/2004)|
|10.||Radomska, Hanna S: 6 articles (04/2006 - 06/2002)|
02/20/2006 - "Thus, our results suggest that therapies targeting the MEK/ERK cascade or development of protein therapies based on transduction of constitutively active C/EBPalpha may prove effective in treatment of FLT3 mutant leukemias resistant to the FLT3 inhibitor therapies."
08/15/2006 - "Moreover, activation of C/EBPalpha eradicated leukemia in 4 of 10 and in 6 of 7 mice injected with STI571-sensitive or -resistant 32D-BCR/ABL cells, respectively. "
01/13/2011 - "Differential effects of sumoylation on the activities of CCAAT enhancer binding protein alpha (C/EBPα) p42 versus p30 may contribute in part, to aberrant C/EBPα activity in acute leukemias."
01/01/2011 - "In this review we will discuss and summarize briefly our current knowledge of epigenetic alterations in leukemias and will turn our attention to a concrete example of epigenetic deregulation of CCAAT/enhancer-binding protein alpha (C/EBPα), a key regulator for granulocytic differentiation of common myeloid progenitor cells in order to highlight the cooperativity of genetic and epigenetic mechanisms acting on this gene during the process of leukemogenesis."
08/26/2010 - "These data reveal that the 3 Tribbles homologs differ in their ability to promote degradation of C/EBPalpha, which account for their differential ability to induce leukemia."
|2.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
02/01/2011 - "Loss of function mutations in CCAAT/enhancer binding protein alpha (CEBPA) have been identified in acute myeloid leukemia (AML) and bi-allelic (double) CEBPA mutations are associated with improved prognosis in cases of cytogenetically normal-AML. "
01/01/2014 - "CCAAT/enhancer-binding protein alpha (CEBPA) mutations are a favorable prognostic factor in adult acute myeloid leukemia (AML) patients; however, few studies have examined their significance in pediatric AML patients. "
08/01/2010 - "In order to evaluate the incidence of CCAAT/enhancer binding protein alpha (cebpa) gene mutation in patients with acute myeloid leukemia (AML), 22 AML patients with normal karyotype (NK-AML) were enrolled in this study, including de novo AML and relapsed AML. "
07/01/2015 - "Aberrant methylation of CCAAT/enhancer-binding protein alpha (CEBPA) promoter has been observed in acute myeloid leukemia. "
07/01/2013 - "To investigate the incidence, molecular features and clinical significance of CCAAT/enhancer binding protein alpha (CEBPA) gene mutation in patients with acute myeloid leukemia (AML). "
10/13/2008 - "Cardiac adiponectin mRNA was significantly higher in Can-early and in Can-late than in Vehicle on days 4 and 7. Cardiac C/EBPalpha in Can-early and Can-early groups was significantly increased on day 4. Myocardial NF-kappaB and TNF-alpha mRNA in Can-early and Can-late groups were significantly reduced on day 7. Candesartan treatment improved myocardial injury in obese mice with acute viral myocarditis and induced expression of cardiac adiponectin with the induction of C/EBPalpha as well as the reduction of cardiac NF-kappaB and TNF-alpha."
01/15/2002 - "Immunohistochemical study of primary tumor specimens showed undetectable or low expression of C/EBPalpha in 23 of 53 specimens. "
01/01/2013 - "Finally, recurrent SIP produced significantly larger amounts of C/EBP-alpha than non- recurrent tumors. "
08/01/2010 - "C/EBP alpha has a crucial role in inducing terminal differentiation and is an established tumor suppressor gene in several cancer models. "
08/01/2010 - "C/EBPalpha (cebpa) is a putative tumor suppressor. "
02/04/2010 - "C/EBPalpha is also a tumor suppressor, but in many tumors its antiproliferative interactions may be attenuated by de-phosphorylation. "
04/01/2009 - "C/EBPalpha promoter activity studies covering -576 bp do not show any effect of E(2); a significant decrease of C/EBPalpha transcriptional activity was found in the C/EBPalpha promoter between -576/416 bp as previously observed when cells were treated with hypoxia alone. "
04/01/2008 - "C/EBP alpha gene promoter studies indicated that hypoxia also repressed the transcription of the gene and identified a hypoxia-responsive element (-522; -527 bp), which binds to hypoxia-inducible factor (HIF)-1 alpha, as essential for down-regulation of C/EBP alpha transcription in hypoxia. "
10/01/2009 - "Hypoxia-HIF-1alpha-C/EBPalpha/Runx1 signaling in leukemic cell differentiation."
04/01/2009 - "Therefore, the observed down-regulation of C/EBPalpha by the H-E(2) combination in T-47D cells is mainly due to the hypoxia effect."
04/01/2008 - "The down-regulation of C/EBP alpha in hypoxia is mediated by HIF-1."
|1.||Messenger RNA (mRNA)
|2.||NF-kappa B (NF-kB)
|3.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|7.||Transcription Factors (Transcription Factor)
|10.||Facilitative Glucose Transport Proteins (Glucose Transporter)
|1.||Protein-Restricted Diet (Diet, Protein Restricted)
|3.||Drug Therapy (Chemotherapy)